Home

Search Abstracts

Browse Sessions

Program Committee

Conference Webcasts

Contact Us

---

Session 111   Poster Abstracts Therapy of HCV in HIV Co-Infected Individuals Wednesday, 1:30 - 3:30 pm Poster Hall

818	Pilot Study of Low Dose Daily Interleukin-2 Plus Pegylated-Interferon-alfa-2b and Ribavirin in Patients with HCV/HIV Co-infection: ACTG A5088 M J Glesby*1, R Bassett2, B Alston3, C J Fichtenbaum4, S Owens5, E L Jacobson1, K A Smith1, K Sherman4, and the ACTG A5088 team 1Cornell Univ, New York, NY, USA; 2Harvard Univ., Boston, MA, USA; 3DAIDS, NIAID, NIH, DHHS, Bethesda, MD, USA; 4Univ. of Cincinnati, OH, USA; and 5Frontier Sci. and Technology Res. Fndn., Amherst, NY, USA
819	Hepatitis C Virus-RNA Clearance in HIV-co-infected Patients with Chronic Hepatitis C Treated with Pegylated Interferon plus Ribavirin V Soriano*, N Camino, M Perez-Olmeda, M Nuñez, I Maida, P Barreiro, L Martin-Carbonero, J Garcia-Samaniego, and J Gonzalez-Lahoz Hosp. Carlos III, Madrid, Spain
820	Viral Kinetics and Early Prediction of Non-response to Pegylated-IFN-alfa-2b and Ribavirin in HCV Genotypes 1/4 according to HIV Serostatus A Moreno*, S García-Garzón, L Moreno, R Bárcena, C Quereda, M L Mateos, A Muriel, J Zamora, M J Pérez-Elías, A Antela, and S Moreno Hosp. Ramon y Cajal, Madrid, Spain
821	Retreatment with Peg-IFN-alfa2a and RBV of Co-infected (HIV/HCV) Non-responders to IFN, Achieves Improved Liver Histology in both Sustained Viral Responders and Non-responders M Rodríguez-Torres*1,2, J Rodriguez-Orengo3, C Ríos-Bedoya2, A Fernández4, E González1, E Aponte1, and V Pérez-Ramos1 1Fndn. de Investigación de Diego, Santurce, PR, USA; 2Ponce Sch. of Med., PR, USA; 3Univ. of Puerto Rico, Recinto de Ciencias Médicas, San Juan, USA; and 4Univ. Pathologists, San Juan, PR, USA
822	Differential Effects of Combined Pegylated Interferon and Ribavirin Therapy on Intracellular Nucleotide Triphosphate Levels in HIV/HCV Co-infected Patients; a Potential Mechanism for Enhanced Toxicity M Hennessy*1, F Mulcahy2, P Spiers3, S Hopkins2, P Hoggard4, S Kewn4, D Back4, and C Bergin2 1Royal Free Hosp., London, UK; 2St .James's Hosp., Dublin, Ireland; 3Trinity Coll., Dublin, Ireland; and 4Univ. of Liverpool, UK
823	Viral Kinetic Modeling in HCV/HIV Co-infected Hemophiliacs Treated with Pegylated Interferon and Ribavirin N J Shire*1, P S Horn1, E M Eyster2, K E Sherman1, and Hemophilia HCV Study Group 1Univ. of Cincinnati, OH, USA and 2Penn State Coll. of Med,. Milton S. Hershey Med. Ctr., Hershey, PA, USA
824	Epoetin-Alfa administered Once Weekly Improves Anemia in HIV/HCV Co-infected Patients Treated with Interferon/Ribavirin Therapy: A Prospective, Randomized Study D Dieterich*1, M Sulkowski2, E Bini3, N Bräu4, C Newman5, D Alvarez6, E DeJesus7, P Bowers8, G Leitz9, and the HIV/HCV Co-infection Study Group 1Mt Sinai Med. Ctr., New York, NY, USA; 2Johns Hopkins Univ., Baltimore, MD, USA; 3New York VA Med. Ctr., NY, USA; 4Bronx VA Med. Ctr., NY, USA; 5Med. Coll. of Georgia, Augusta, GA, USA; 6Drexel Univ. Coll. of Med., Philadelphia, PA, USA; 7IDC Res. Initiative, Altamonte Springs, FL, USA; 8Johnson & Johnson Pharm. Res. and Devt., Raritan, NJ, USA; and 9Ortho Biotech Products, L.P., Bridgewater, NJ, USA
825	Efficacy of Interferon and Ribavirin Therapy in HIV/HCV Co-infected Patients: Sustained Viral Response Is Associated with a Rise in CD4 Lymphocyte Count A Uriel*, D Carriero, J Lucas, A Reichenberg, H Freemantle, D Goldman, S Levitan, and D Dieterich Mount Sinai Med. Ctr., New York, NY, USA